Table 1.
Characteristics of participants according to studya.
| Crisis (n = 191) | 2nd Line (n = 394) | TDF (n = 333) | Total (n = 918) | |
|---|---|---|---|---|
| Age (yr) | 42 [36, 50] | 42 [36, 49] | 41 [36, 48] | 42 [36, 49] |
| Gender | ||||
| Female | 62% | 60% | 55% | 59% |
| Male | 38% | 40% | 45% | 41% |
| Viral Load (VL) | 44 [<40, <400] | <40 [<40, 430] | <40 [<40, <40] | <40 [<40, 192] |
| VL > 1000 | 15% | 21% | 10% | 16% |
| CD4 Count (NA=19) | 361 [249, 503] | 282 [182, 419] | 336 [226, 470] | 314 [210, 453] |
| CD4% (NA=19) | 23 [17, 28] | 17 [12, 23] | 21 [15, 28] | 19 [14, 26] |
| Most Recent CD4 | 376 [262, 553] | 273 [165, 409] | 321 [210, 467] | 311 [201, 458] |
| Most Recent CD4% | 20 [16, 26] | 16 [11, 21] | 2 [15, 27] | 18 [13, 25] |
| Chg of CD4/yr b | −14.3 [−121, 94] | 0.5 [−75, 170] | 0.0 [−63, 112] | 0.0 [−85, 127] |
| Chg of CD4%/yr b | 2.2 [.0, 5.3] | 2.0 [.0, 6.9] | .9 [−1.3, 6.5] | 1.7 [.0, 6.5] |
| Yrs on Current ART | 2.7 [2.1, 4.4] | 1.1 [.6, 3.3] | 1.7 [1.2, 2.2] | 1.8 [.9, 2.7] |
| Yrs on ART | 4.3 [3.6, 5.1] | 5.9 [4.4, 7.4] | 2.1 [1.4, 4.6] | 4.5 [2.6, 6.2] |
| ART adherence c | ||||
| Most | 0.0% | 0.8% | 0.3% | 0.4% |
| Some | 1.6% | 5.1% | 1.8% | 3.2% |
| None | 98.4% | 94.1% | 97.9% | 96.4% |
| WHO Stage (NA=4) | ||||
| Stage 1 | 18% | 14% | 24% | 19% |
| Stage 2 | 18% | 16% | 16% | 17% |
| Stage 3 | 46% | 48% | 43% | 45% |
| Stage 4 | 18% | 22% | 17% | 19% |
| ART | ||||
| 1st line | 100% | 0% | 100% | 57% |
| 2nd line | 0% | 100% | 0% | 43% |
a
Continuous variables are summarized by median and interquartile range (IQR), and categorical variables by percentages. Numbers inside [ ] are IQR;
b
Change = (value at enrollment - most recent before enrollment)/(time between the two visits);
c
ART adherence of last week by the self-report percentage: Most (>50%), Some (<50%), None (0%).
ART = antiretroviral therapy; chg = change; NA = not available; TDF = tenofovir; WHO = World Health Organization; yr = year.